Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

NCT05016882 on ClinicalTrials.gov · last registry update 2025-11-19

An unusually large phase 2: 698 participants, more than double the 110 typical for the stage. The sponsor logged completion for 17 December 2024. Primary outcome, as filed: Improvement in liver fibrosis and no worsening of NASH (Yes/No). semaglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 698
Started: 2021-08-31
Primary completion: 2024-12-17 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Improvement in liver fibrosis and no worsening of NASH (Yes/No)

Conditions studied

Non-alcoholic Steatohepatitis

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.